Stereoselective synthesis of new rac-quercitols containing hydroxymethyl groups as glucosidase inhibitors

Stereoselective and efficient synthesis of hydroxymethyl-substituted rac-quercitols (13–15) was achieved, starting from cis-furan (Kobayashi, 2008) with photooxygenation reaction, which is readily available by the reduction of cis-phtalic anhydride. α- and β-Glucosidase enzyme activity of the target molecules was evaluated and good inhibitor activity was seen. One- and two-dimensional NMR spectroscopy, IR spectroscopy and X-ray crystallography were utilized in the structure characterization of products.     

Antimicrobial,anticoagulant, and cytotoxic evaluation of multidrug resistance of new 1,4-dihydropyridine derivatives

A new series of 1,4-dihydropyridine derivatives (2a–h, 3a–e, and 4a–e) were systematically designed and synthesized via ultrasound irradiation methods with easy work-up and good yields. Compounds structures were confirmed by IR, ¹H NMR, ¹³C NMR, and mass spectra. The synthesized compounds were screened for both antimicrobial and anticoagulant activities. Compound 2e (MIC: 0.25?μg/mL) was highly active against Escherichia coli and compound 2c (MIC: 0.5?μg/mL) was also highly active against Pseudomonas aeruginosa compared with ciprofloxacin. (MIC: 1?μg/mL) The antifungal activity of 2c (MIC: 0.5?μg/mL) against Candida albicans was high relative to that of clotrimazole (MIC: 1?μg/mL). Anticoagulant activity was determined by activated partial thromboplastin time (APTT) and prothrombin time (PT) coagulation assays. Compound 4-(4-hydroxyphenyl)-2,6-dimethyl-N³,N⁵-bis(5-phenyl-1,3,4-thiadiazol-2-yl)-1,4-dihydropyridine-3,5-dicarboxamide 3d (>1000?s in APTT assays) was highly active in anticoagulant screening compared with the reference of heparin.Cytotoxicity was evaluated using HepG2 (liver), HeLa (cervical), and MCF-7 (breast) cancer cell lines, with high toxicities observed for 2c (GI₅₀?=?0.02?μm) against HeLa cell line and 2e (GI₅₀?=?0.03?μm) equipotant against MCF-7 cell line. Therefore, the compounds 2e, 2c and 3d can serve as lead molecules for the development of new classes of antimicrobial and anticoagulant agent.     

Genome Characteristics of the Cyclophragma Undans Nucleopolyhedrovirus: A Distinct Species in Group Ⅰ of Alphabaculovirus

The Cyclophragma undans nucleopolyhedrovirus(Cyun NPV), a potential pest control agent, was isolated from Cyclophragma undans(Lepidoptera: Lasiocampidae), an important forest pest. In the present study, we performed detailed genome analysis of Cyun NPV and compared its genome to those of other Group Ⅰ alphabaculoviruses. Sequencing of the Cyun NPV genome using the Roche 454 sequencing system generated 142,900 bp with a G + C content of 45%. Genome analysis predicted a total of 147 hypothetical open reading frames comprising 38 baculoviral core genes, 24 lepidopteran baculovirus conserved genes, nine Group Ⅰ Alphabaculovirus conserved genes, 71 common genes, and five genes that are unique to Cyun NPV. In addition, the genome contains 13 homologous repeated sequences(hrs). Phylogenetic analysis groups Cyun NPV under a distinct branch within clade ‘‘a' of Group Ⅰ in the genus Alphabaculovirus. Unlike other members of Group Ⅰ, Cyun NPV harbors only nine of the 11 genes previously determined to be specific to Group Ⅰ viruses.Furthermore, the Cyun NPV lacks the tyrosine phosphatase gene and the ac30 gene. The Cyun NPV F-like protein contains two insertions of continuous polar amino acids, one at the conventional fusion peptide and a second insertion at the pretransmembrane domain. The insertions are likely to affect the fusion function and suggest an evolutionary process that led to inactivation of the F-like protein. The above findings imply that Cyun NPV is a distinct species under Group Ⅰ Alphabaculovirus.     

Identification of purple blotch pathogen of shallot by PCR using specific primer for Alternaria genus

Purple blotch (Alternaria porri), having symptom similar to stemphylium blight (Stemphylium vesicarium), is one of the important diseases that significantly lowered shallot yield in Indonesia. However, stemphylium blight has never been reported. Purple blotch pathogens from farmers’ crops in Bantul and experimental crop in Centre of Innovative Agricultural Technology Universitas Gadjah Mada (CIAT-UGM) Sleman Regencies were identified to observe whether Stemphylium sp. was found with A. porri. Thirteen isolates obtained showed variability in colony texture, colour and pigmentation. DNA fingerprinting through Polymerase Chain Reaction of BOX and Enterobacterial Repetitive Intergenic Consensus region dispersed those isolates into two main groups. Identification using Alternaria-specific primers, Dir1ITSAlt/Inv1ITSAlt revealed that 10 isolates were Stemphylium sp. and 3 isolates were Alternaria sp. A. porri was only identified from CIAT-UGM. This finding emphasise that the Alternaria-specific primer was able to amplify Stemphylium sp. Besides, stemphylium blight disease may have been occurred in farmers’ crops in Bantul.     

Sativanine-a and sativanine-b,two new cyclopeptide alkaloids from the bark of Zizyphus sativa

From the bark of Zizyphus sativa, in addition to already described cyclopeptide alkaloids, two new compounds of this class, sativanine-A(1) and sativanine-B(2), were isolated. Both alkaloids contain 14-membered ring systems. 1 belongs to the integerrine type, while 2 is similar to nummularine-G, with an additional ring in the side chain.     

Structural changes in root and shoot ofBacopa monniera in response to salt stress

Various concentrations of salt (NaCI) were shown to have an influence on the differentiation of tissues in the root and stem ofBacopa monniera (L) Wettst. Higher concentrations induced drastic changes in roots grown on salt-supplemented media; epidermal and cortical cells experienced changes in shape, size, and orientation and/or were got disintegrated. A low concentration of salt induced a profuse development of root hairs which gradually disappeared at higher concentrations. Air spaces in the stem cortex were enlarged and xylem cell walls in the vascular ring were thickened.     

Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987‐2013

More than fifteen years ago, it was noted that the failure rate of antidepressant clinical trials was high, and such negative outcomes were thought to be related to the increasing magnitude of placebo response. However, there is considerable debate regarding this phenomenon and its relationship to outcomes in more recent antidepressant clinical trials. To investigate this, we accessed the US Food and Drug Administration (FDA) reviews for sixteen antidepressants (85 trials, 115 trial arms, 23,109 patients) approved between 1987 and 2013. We calculated the magnitude of placebo and antidepressant responses, antidepressant‐placebo differences, as well as the effect sizes and success rates, and compared these measures over time. Exploratory analysis investigated potential changes in trial design and conduct over time. As expected, the magnitude of placebo response has steadily grown in the past 30 years, increasing since 2000 by 6.4% (r=0.46, p<0.001). Contrary to expectations, a similar increase has occurred in the magnitude of antidepressant response (6.0%, r=0.37, p<0.001). Thus, the effect sizes (0.30 vs. 0.29, p=0.42) and the magnitude of antidepressant‐placebo differences (10.5% vs. 10.3%, p=0.37) have remained statistically equivalent. Furthermore, the frequency of positive trial arms has gone up in the past 15 years (from 47.8% to 63.8%), but this difference in frequency has not reached statistical significance. Trial design features that were previously associated with a possible lower magnitude of placebo response were not implemented, and their relationship to the magnitude of placebo response could not be replicated. Of the 34 recent trials, two implemented enhanced interview techniques, but both of them were unsuccessful. The results of this study suggest that the relationship between the magnitude of placebo response and the outcome of antidepressant clinical trials is weak at best. These data further indicate that antidepressant‐placebo differences are about the same for all of the sixteen antidepressants approved by the FDA in the past thirty years.